Hosted on MSN4m
Summit Therapeutics advances ivonescimab with Pfizer collaboration and expanded trials
Earnings Call Insights: Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2024 Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to evaluate ivonescimab in ...
Summit Therapeutics (NASDAQ:SMMT) Given Buy Rating at HC Wainwright
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...
You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's al…
Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...